Investing.com investing.com 12 Jan, 2021 12:00 am

Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way By Reuters

Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way By Reuters
Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way

To be sure, last year Novavax awarded more than $85 million worth of stock options to executives, including $41.Executives at Emergent BioSolutions Inc, Pfizer and Johnson & Johnson, also recipients of federal funds, sold $24 million, $10 million and $4 million worth of stock, respectively, according to Accountable.Moderna executives sold $166 million worth, according to Accountable.Pfizer Inc's vaccine was the first to be approved by the United States on Dec.

Novavax, meanwhile, announced last month that it had begun a late-stage trial of its COVID-19 vaccine in the United States, after delaying it twice due to issues in scaling up its manufacturing.Early-stage data from Novavax's small clinical trial of its vaccine have shown it produced high levels of virus-fighting antibodies and the company has already inked supply deals for it with countries including Japan, Canada, Australia and the UK as well as with the United States.

Read full story at investing.com